Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma
Authors
Keywords
-
Journal
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2020-08-19
DOI
10.1080/13506129.2020.1808783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AG10 CONSISTENTLY STABILIZES TRANSTHYRETIN TO A HIGH LEVEL IN BOTH WILD TYPE AND MUTANT AMYLOID CARDIOMYOPATHY: RESPONDER ANALYSES FROM A PHASE 2 CLINICAL TRIAL
- (2019) Jonathan C. Fox et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
- (2019) Daniel P. Judge et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study
- (2019) Josep Gamez et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Transthyretin Amyloid Cardiomyopathy
- (2019) Frederick L. Ruberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers
- (2019) Jonathan C. Fox et al. Clinical Pharmacology in Drug Development
- Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients
- (2018) Cecilia Monteiro et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis
- (2018) Hannah Rosenblum et al. Circulation-Heart Failure
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- AG10, A Novel, Potent and Selective Transthyretin Stabilizer, is Well Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers
- (2018) Jennifer L. Hellawell et al. JOURNAL OF CARDIAC FAILURE
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
- (2018) Mathew S. Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy
- (2018) Teresa Coelho et al. NEUROLOGY
- Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
- (2017) Joseph D. Schonhoft et al. Science Translational Medicine
- Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
- (2016) Ricardo Sant'Anna et al. Nature Communications
- Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)
- (2015) Younhee Cho et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Targeting protein aggregation for the treatment of degenerative diseases
- (2015) Yvonne S. Eisele et al. NATURE REVIEWS DRUG DISCOVERY
- Repurposing Diflunisal for Familial Amyloid Polyneuropathy
- (2015) John L. Berk et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case
- (2014) Lei Z. Robinson et al. BIOCHEMISTRY
- Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange
- (2014) Irit Rappley et al. BIOCHEMISTRY
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
- (2013) Teresa Coelho et al. JOURNAL OF NEUROLOGY
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
- (2013) S. C. Penchala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
- (2012) T. Coelho et al. NEUROLOGY
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
- (2012) C. E. Bulawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study
- (2011) Mitsuharu Ueda et al. MODERN PATHOLOGY
- A Stilbene That Binds Selectively to Transthyretin in Cells and Remains Dark until It Undergoes a Chemoselective Reaction To Create a Bright Blue Fluorescent Conjugate
- (2010) Sungwook Choi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2‐macroglobulinandtau: A population‐based autopsy study
- (2008) Maarit Tanskanen et al. ANNALS OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started